Premium
APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern
Author(s) -
Risacher Shan L.,
Kim Sungeun,
Nho Kwangsik,
Foroud Tatiana,
Shen Li,
Petersen Ronald C.,
Jack Clifford R.,
Beckett Laurel A.,
Aisen Paul S.,
Koeppe Robert A.,
Jagust William J.,
Shaw Leslie M.,
Trojanowski John Q.,
Weiner Michael W.,
Saykin Andrew J.
Publication year - 2015
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2015.03.003
Subject(s) - apolipoprotein e , neurodegeneration , cerebrospinal fluid , alzheimer's disease neuroimaging initiative , amyloid (mycology) , atrophy , disease , alzheimer's disease , psychology , medicine , pathology , temporal lobe , neuroimaging , neuroscience , epilepsy
This study assessed apolipoprotein E ( APOE ) ε4 carrier status effects on Alzheimer's disease imaging and cerebrospinal fluid (CSF) biomarkers in cognitively normal older adults with significant memory concerns (SMC). Methods Cognitively normal, SMC, and early mild cognitive impairment participants from Alzheimer's Disease Neuroimaging Initiative were divided by APOE ε4 carrier status. Diagnostic and APOE effects were evaluated with emphasis on SMC. Additional analyses in SMC evaluated the effect of the interaction between APOE and [ 18 F]Florbetapir amyloid positivity on CSF biomarkers. Results SMC ε4+ showed greater amyloid deposition than SMC ε4−, but no hypometabolism or medial temporal lobe (MTL) atrophy. SMC ε4+ showed lower amyloid beta 1–42 and higher tau/p‐tau than ε4−, which was most abnormal in APOE ε4+ and cerebral amyloid positive SMC. Discussion SMC APOE ε4+ show abnormal changes in amyloid and tau biomarkers, but no hypometabolism or MTL neurodegeneration, reflecting the at‐risk nature of the SMC group and the importance of APOE in mediating this risk.